Literature DB >> 7545243

Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules.

H Golding1, D S Dimitrov, J Manischewitz, C C Broder, J Robinson, S Fabian, D R Littman, C K Lapham.   

Abstract

The entry of human immunodeficiency virus type 1 into cells proceeds via a fusion mechanism that is initiated by binding of the viral glycoprotein gp120-gp41 to its cellular receptor CD4. Species- and tissue-specific restrictions to viral entry suggested the participation of additional membrane components in the postbinding fusion events. In a previous study (H. Golding, J. Manischewitz, L. Vujcic, R. Blumenthal, and D. Dimitrov, J. Virol. 68:1962-1968, 1994), it was found that phorbol myristate acetate (PMA) inhibits human immunodeficiency virus type 1 envelope-mediated cell fusion by inducing down modulation of an accessory component(s) in the CD4-expressing cells. The fusion inhibition was seen in a variety of cells, including T-cell transfectants expressing engineered CD4 receptors (CD4.401 and CD4.CD8) which are not susceptible to down modulation by PMA treatment. In the current study, it was found that preincubation of A2.01.CD4.401 cells with soluble monomeric gp120 for 1 h at 37 degrees C primed them for PMA-induced down modulation (up to 70%) of the tailless CD4 receptors. The gp120-priming effect was temperature dependent, and the down modulation may have occurred via clathrin-coated pits. Importantly, nonhuman cell lines expressing tailless CD4 molecules did not down modulate their CD4 receptors under the same conditions. The gp120-dependent PMA-induced down modulation of tailless CD4 receptors could be efficiently blocked by the human monoclonal antibodies 48D and 17B, which bind with increased avidity to gp120 that was previously bound to CD4 (M. Thali, J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski, J. Virol. 67:3978-3988, 1993). These findings suggest that gp120 binding to cellular CD4 receptors induces conformational changes leading to association of the gp120-CD4 complexes with accessory transmembrane molecules that are susceptible to PMA-induced down modulation and can target the virions to clathrin-coated pits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545243      PMCID: PMC189511     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Phosphorylation-dependent down-modulation of CD4 requires a specific structure within the cytoplasmic domain of CD4.

Authors:  J Shin; R L Dunbrack; S Lee; J L Strominger
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

2.  Syncytium formation of human and non-human cells by recombinant vaccinia viruses carrying the HIV env gene and human CD4 gene.

Authors:  N Aoki; T Shioda; H Satoh; H Shibuta
Journal:  AIDS       Date:  1991-07       Impact factor: 4.177

3.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Several CD4 domains can play a role in human immunodeficiency virus infection in cells.

Authors:  L Poulin; L A Evans; S B Tang; A Barboza; H Legg; D R Littman; J A Levy
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus.

Authors:  L Bergeron; N Sullivan; J Sodroski
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Physical association of CD4 with the T cell receptor.

Authors:  U Dianzani; A Shaw; B K al-Ramadi; R T Kubo; C A Janeway
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

7.  Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  T Dragic; L Picard; M Alizon
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells.

Authors:  A Pelchen-Matthews; J E Armes; G Griffiths; M Marsh
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.

Authors:  F Celada; C Cambiaggi; J Maccari; S Burastero; T Gregory; E Patzer; J Porter; C McDanal; T Matthews
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  15 in total

1.  Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Authors:  S Lee; K Peden; D S Dimitrov; C C Broder; J Manischewitz; G Denisova; J M Gershoni; H Golding
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

Authors:  K Salzwedel; E D Smith; B Dey; E A Berger
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae.

Authors:  H A Anderson; Y Chen; L C Norkin
Journal:  Mol Biol Cell       Date:  1996-11       Impact factor: 4.138

Review 4.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

5.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.

Authors:  D G Fox; P Balfe; C P Palmer; J C May; C Arnold; J A McKeating
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  S Lee; C K Lapham; H Chen; L King; J Manischewitz; T Romantseva; H Mostowski; T S Stantchev; C C Broder; H Golding
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

Authors:  J F Berson; D Long; B J Doranz; J Rucker; F R Jirik; R W Doms
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.

Authors:  Quan-En Yang; Andrew G Stephen; Joseph W Adelsberger; Paula E Roberts; Weimin Zhu; Michael J Currens; Yaxiong Feng; Bruce J Crise; Robert J Gorelick; Alan R Rein; Robert J Fisher; Robert H Shoemaker; Shizuko Sei
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

10.  Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human neuroblastoma CHP100 cells involves activation of the arachidonate cascade.

Authors:  M Maccarrone; M Navarra; M T Corasaniti; G Nisticò; A Finazzi Agrò
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.